نتائج البحث - Yazan Numan

  • يعرض 1 - 2 نتائج من 2
تنقيح النتائج
  1. 1
    First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia

    First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia حسب Yazan Numan, Mansour Alfayez, Abhishek Maiti, Yesid Alvarado, Elias Jabbour, Alessandra Ferrajoli, Sergej Konoplev, Hagop M. Kantarjian, Prithviraj Bose

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Gilteritinib clinical activity in relapsed/refractory <scp><i>FLT3</i></scp> mutated <scp>acute myeloid leukemia</scp> previously treated with <scp><i>FLT3</i></scp> inhibitors

    Gilteritinib clinical activity in relapsed/refractory <scp><i>FLT3</i></scp> mutated <scp>acute myeloid leukemia</scp> previously treated with <scp><i>FLT3</i></scp> inhibitors حسب Yazan Numan, Zaid Abdel Rahman, Justin Grenet, Stéphanie Boisclair, Jan Philipp Bewersdorf, Cailin Collins, Dylan Barth, Martina Fraga, Dale L. Bixby, Amer M. Zeidan, Musa Yılmaz, Pankil Desai, Gabriel N. Mannis, Yehuda E. Deutsch, Yasmin Abaza, Shira Dinner, Olga Frankfurt, Mark R. Litzow, Aref Al‐Kali, James M. Foran, Lisa Z. Sproat, Borko Jovanovic, Naval Daver, Alexander E. Perl, Jessica K. Altman

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: